Literature DB >> 26486331

MRI-Guided HIFU Methods for the Ablation of Liver and Renal Cancers.

Baudouin Denis de Senneville1,2, Chrit Moonen3, Mario Ries4.   

Abstract

MRI-guided High Intensity Focused Ultrasound (MRI-HIFU) is a promising method for the non-invasive ablation of pathological tissue in many organs, including mobile organs such as liver and kidney. The possibility to locally deposit thermal energy in a non-invasive way opens a path towards new therapeutic strategies with improved reliability and reduced associated trauma, leading to improved efficacy, reduced hospitalization and costs. Liver and kidney tumors represent a major health problem because not all patients are suitable for curative treatment with surgery. Currently, radio-frequency is the most used method for percutaneous ablation. The development of a completely non-invasive method based on MR guided high intensity focused ultrasound (HIFU) treatments is of particular interest due to the associated reduced burden for the patient, treatment related patient morbidity and complication rate. The objective of MR-guidance is hereby to control heat deposition with HIFU within the targeted pathological area, despite the physiological motion of these organs, in order to provide an effective treatment with a reduced duration and an increased level of patient safety. Regarding this, several technological challenges have to be addressed: Firstly, the anatomical location of both organs within the thoracic cage requires inter-costal ablation strategies, which preserve the therapeutic efficiency, but prevent undesired tissue damage to the ribs and the intercostal muscle. Secondly, both therapy guidance and energy deposition have to be rendered compatible with the continuous physiological motion of the abdomen.

Entities:  

Keywords:  MRI HIFU; Real-time; Tumor ablation

Mesh:

Year:  2016        PMID: 26486331     DOI: 10.1007/978-3-319-22536-4_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  Simultaneous MR thermometry and acoustic radiation force imaging using interleaved acquisition.

Authors:  Joshua T de Bever; Henrik Odéen; Lorne W Hofstetter; Dennis L Parker
Journal:  Magn Reson Med       Date:  2017-08-10       Impact factor: 4.668

2.  In vivo study of enhanced chemotherapy combined with ultrasound image-guided focused ultrasound (USgFUS) treatment for pancreatic cancer in a xenograft mouse model.

Authors:  Eun-Joo Park; Yun Deok Ahn; Jae Young Lee
Journal:  Eur Radiol       Date:  2018-03-29       Impact factor: 5.315

3.  MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?

Authors:  Zhaonan Li; Chaoyan Wang; Jing Li; Zaoqu Liu; Dechao Jiao; Xinwei Han
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

4.  Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) after High-Intensity Ultrasound (HIUS).

Authors:  Veria Khosrawipour; Sören Reinhard; Alice Martino; Tanja Khosrawipour; Mohamed Arafkas; Agata Mikolajczyk
Journal:  Int J Surg Oncol       Date:  2019-12-12

5.  Immune modulation resulting from MR-guided high intensity focused ultrasound in a model of murine breast cancer.

Authors:  Brett Z Fite; James Wang; Aris J Kare; Asaf Ilovitsh; Michael Chavez; Tali Ilovitsh; Nisi Zhang; Weiyu Chen; Elise Robinson; Hua Zhang; Azadeh Kheirolomoom; Matthew T Silvestrini; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Ryan R Davis; Clifford G Tepper; Alexander D Borowsky; Katherine W Ferrara
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.996

6.  Intraperitoneal chemotherapy of the peritoneal surface using high-intensity ultrasound (HIUS): investigation of technical feasibility, safety and possible limitations.

Authors:  Hien Lau; Tanja Khosrawipour; Agata Mikolajczyk; Piotr Frelkiewicz; Jakub Nicpon; Mohamed Arafkas; Alessio Pigazzi; Wolfram Trudo Knoefel; Veria Khosrawipour
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.